Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Vericiguat Pediatric Suspensions
NCT05086952Phase 1Completed
- Sponsor
- Bayer
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Vericiguat oral suspension (Formulation 4) in heart failure (HF) (4 arms), sponsored by Bayer. Primary endpoints: Area Under the Curve at 72 hours and Maximum Plasma Concentration at 72 hours. Started Oct 2021; status: completed.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05086952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05086952.